Gene: SLC35D2

11046
HFRC1|SQV7L|UGTrel8|hfrc
solute carrier family 35 member D2
protein-coding
9q22.32
Ensembl:ENSG00000285269 MIM:609182 Vega:OTTHUMG00000020293 UniprotKB:Q76EJ3
NC_000009.12
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.496e-1 (AD)  8.790e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RHOG0.908
LITAF0.907
WIPF10.881
CD90.875
REEP30.871
CDC42EP10.871
CLIC40.863
FAM114A10.863
SPATA130.859
SEPT100.859

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CDH22-0.558
FBLN7-0.546
BEAN1-0.538
CUX2-0.537
KCNQ4-0.525
KCNK3-0.521
HCN4-0.518
OPRD1-0.507
KCNG1-0.503
ASB2-0.503

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0512461-methylanthracene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC35D2 mRNA28329830
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC35D2 mRNA"19167446
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of SLC35D2 mRNA"21346803
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of SLC35D2 mRNA"21346803
C4879483-iodothyronamineSLC35D2 mRNA affects the uptake of 3-iodothyronamine19074582
D000082AcetaminophenAcetaminophen results in decreased expression of SLC35D2 mRNA21420995
D016604Aflatoxin B1Aflatoxin B1 affects the expression of SLC35D2 protein20106945
D000393Air PollutantsAir Pollutants analog results in decreased expression of SLC35D2 mRNA21757418
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of SLC35D2 mRNA21715664
D004958Estradiol[bisphenol A co-treated with Estradiol] results in increased expression of SLC35D2 mRNA26496021
C044887beta-methylcholinebeta-methylcholine affects the expression of SLC35D2 mRNA21179406
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in increased expression of SLC35D2 mRNA26496021
D002220CarbamazepineCarbamazepine affects the expression of SLC35D2 mRNA25979313
D002509CephaloridineCephaloridine results in increased expression of SLC35D2 mRNA18500788
D002922CiguatoxinsCiguatoxins affects the expression of SLC35D2 mRNA18353800
C012843cinnamic aldehydecinnamic aldehyde results in decreased expression of SLC35D2 mRNA17178418
D019327Copper SulfateCopper Sulfate results in decreased expression of SLC35D2 mRNA19549813
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC35D2 mRNA"19167446
D003375CoumestrolCoumestrol results in decreased expression of SLC35D2 mRNA19167446
D016572CyclosporineCyclosporine results in decreased expression of SLC35D2 mRNA20106945
D016572CyclosporineCyclosporine results in increased expression of SLC35D2 mRNA27989131
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35D2 mRNA22079256
C007738fluoranthene[1-methylanthracene co-treated with fluoranthene] results in decreased expression of SLC35D2 mRNA28329830
D005485FlutamideFlutamide results in decreased expression of SLC35D2 mRNA24793618
C039281furanfuran results in increased expression of SLC35D2 mRNA24183702
C492448ICG 001ICG 001 results in increased expression of SLC35D2 mRNA26191083
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SLC35D2 mRNA25613284
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of SLC35D2 mRNA23086925
D007854LeadLead results in increased expression of SLC35D2 mRNA19921347
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of SLC35D2 mRNA23179753
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in decreased expression of SLC35D2 mRNA22401849
C016030pantogabpantogab results in decreased expression of SLC35D2 mRNA17379144
D010416PentachlorophenolPentachlorophenol results in decreased expression of SLC35D2 mRNA23892564
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC35D2 mRNA19710929
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC35D2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of SLC35D2 mRNA22079256
D011441PropylthiouracilPropylthiouracil affects the expression of SLC35D2 mRNA24780913
D012834SilverSilver results in increased expression of SLC35D2 mRNA27131904
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SLC35D2 mRNA26290441
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SLC35D2 mRNA25613284
D013853ThioacetamideThioacetamide results in increased expression of SLC35D2 mRNA23411599
D014635Valproic AcidValproic Acid affects the expression of SLC35D2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SLC35D2 mRNA23527032|2915479
D014638VanadatesVanadates results in decreased expression of SLC35D2 mRNA22714537
C100058vanillinvanillin results in decreased expression of SLC35D2 mRNA17178418
C111237vorinostatvorinostat results in decreased expression of SLC35D2 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005338nucleotide-sugar transmembrane transporter activity-NAS9927678  
GO:0005338nucleotide-sugar transmembrane transporter activity-TAS-  
GO:0015165pyrimidine nucleotide-sugar transmembrane transporter activity-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0006024glycosaminoglycan biosynthetic process-TAS-  
GO:0008150biological_process-ND-  
GO:0008643carbohydrate transport-IEA-  
GO:0018146keratan sulfate biosynthetic process-TAS-  
GO:0090481pyrimidine nucleotide-sugar transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005575cellular_component-ND-  
GO:0005794Golgi apparatus-IDA-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1630316Glycosaminoglycan metabolismTAS
R-HSA-1638074Keratan sulfate/keratin metabolismTAS
R-HSA-1638091Heparan sulfate/heparin (HS-GAG) metabolismTAS
R-HSA-2022854Keratan sulfate biosynthesisTAS
R-HSA-2022928HS-GAG biosynthesisTAS
R-HSA-382551Transport of small moleculesTAS
R-HSA-425397Transport of vitamins, nucleosides, and related moleculesTAS
R-HSA-425407SLC-mediated transmembrane transportTAS
R-HSA-71387Metabolism of carbohydratesTAS
R-HSA-727802Transport of nucleotide sugarsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23144319Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study. (2013 Feb)Lee YCarcinogenesis